Ingrezza is an anti-dyskinesia drug owned by Neurocrine. The drug contains valbenazine tosylate as an active ingredient and was first authorized for market use on April 11, 2017. This drug is available in capsule;oral dosage forms.
The generics of Ingrezza are expected to be available after August 10, 2040. This is determined by the expiration of the patent US10940141 on that same date. It is to be noted that the release of the generic could be sooner if there is a successful Para IV filing that challenges the patent validity or claims it is not infringed.
Ingrezza is primarily used for the treatment of tardive dyskinesia. The active ingredient, valbenazine tosylate, contributes to its effectiveness in treating this condition. Furthermore, methods have been established for administering Valbenazine while avoiding concomitant use of a strong cyp3a4 inducer. This not only improves the effectiveness of the drug but also reduces the risk of potential side effects. In addition to tardive dyskinesia, the drug can be used for treating Huntington's chorea.
Ingrezza holds 22 patents, none of which have expired. The final patent is projected to expire on August 10, 2040, marking the earliest date for the availability of Ingrezza generics. This patent, US10940141, relates to methods for the administration of certain VMAT2 inhibitors. Below are the details of the patent: